首页 > 最新文献

World journal of methodology最新文献

英文 中文
Research surveys and their evolution: Past, current and future uses in healthcare. 研究调查及其演变:过去、现在和未来在医疗保健中的应用。
Pub Date : 2024-12-20 DOI: 10.5662/wjm.v14.i4.93559
Michael Colwill, Richard Pollok, Andrew Poullis

Research surveys are believed to have originated in antiquity with evidence of them being performed in ancient Egypt and Greece. In the past century, their use has grown significantly and they are now one of the most frequently employed research methods including in the field of healthcare. Modern validation techniques and processes have allowed researchers to broaden the scope of qualitative data they can gather through these surveys such as an individual's views on service quality to nationwide surveys that are undertaken regularly to follow healthcare trends. This article focuses on the evolution and current utility of research surveys, different methodologies employed in their creation, the advantages and disadvantages of different forms and their future use in healthcare research. We also review the role artificial intelligence and the importance of increased patient participation in the development of these surveys in order to obtain more accurate and clinically relevant data.

研究调查被认为起源于古代,有证据表明它们在古埃及和希腊进行。在过去的一个世纪里,它们的使用显著增长,它们现在是最常用的研究方法之一,包括在医疗保健领域。现代验证技术和流程使研究人员能够扩大他们可以通过这些调查收集的定性数据的范围,例如个人对服务质量的看法,以及定期进行的全国性调查,以跟踪医疗保健趋势。本文的重点是研究调查的演变和当前的效用,在其创建中采用的不同方法,不同形式的优点和缺点以及它们在医疗保健研究中的未来使用。我们还回顾了人工智能的作用以及增加患者参与这些调查的重要性,以获得更准确和临床相关的数据。
{"title":"Research surveys and their evolution: Past, current and future uses in healthcare.","authors":"Michael Colwill, Richard Pollok, Andrew Poullis","doi":"10.5662/wjm.v14.i4.93559","DOIUrl":"10.5662/wjm.v14.i4.93559","url":null,"abstract":"<p><p>Research surveys are believed to have originated in antiquity with evidence of them being performed in ancient Egypt and Greece. In the past century, their use has grown significantly and they are now one of the most frequently employed research methods including in the field of healthcare. Modern validation techniques and processes have allowed researchers to broaden the scope of qualitative data they can gather through these surveys such as an individual's views on service quality to nationwide surveys that are undertaken regularly to follow healthcare trends. This article focuses on the evolution and current utility of research surveys, different methodologies employed in their creation, the advantages and disadvantages of different forms and their future use in healthcare research. We also review the role artificial intelligence and the importance of increased patient participation in the development of these surveys in order to obtain more accurate and clinically relevant data.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"93559"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatocellular carcinoma national burden across different geographical regions in the United States between 2001 and 2020. 2001年至2020年美国不同地理区域的肝细胞癌国家负担
Pub Date : 2024-12-20 DOI: 10.5662/wjm.v14.i4.95598
Yazan Abboud, Raj Malhotra, Muhammad Hassaan Arif Maan, Anna Mathew, Ibrahim Abboud, Chun-Wei Pan, Saqr Alsakarneh, Fouad Jaber, Islam Mohamed, David Kim, Nikolaos T Pyrsopoulos

Background: While prior data showed an increasing incidence of hepatocellular carcinoma (HCC) in the United States, there are limited comprehensive and comparative data on the geographical variations of HCC trends in different demographic-specific populations.

Aim: To evaluate sex and age-specific incidence rates and time trends in different geographical regions in the United States.

Methods: Age-adjusted HCC incidence rates were collected from the United States Cancer Statistics (USCS) database which covers approximately 98% of the population in the United States. HCC rates were stratified by sex, age, and geographical region. annual percentage change (APC) and average APC (AAPC) were estimated using Joinpoint Regression. A pairwise comparison was conducted between sex-specific trends.

Results: There were 467344 patients diagnosed with HCC in the United States in the USCS database between 2001 and 2020. The rates and trends varied by geographical region. When looking at the West region (115336 patients), incidence rates of HCC were overall increasing and also increasing in older adults. However, when evaluating younger adults, HCC incidence rates decreased in men but not in women with a sex-specific absolute AAPC-difference of 2.15 (P = 0.005). When evaluating the Midwest region (84612 patients), similar results were seen. While incidence rates were increasing in the overall population and in older adults as well, they were decreasing in younger men but not in women with a sex-specific absolute AAPC-difference of 1.61 (P < 0.001). For the Northeast region (87259 patients), the analysis showed similar results with decreasing HCC incidence rates in younger men but not counterpart women (Sex-specific AAPC-difference = 3.26, P < 0.001). Lastly, when evaluating the south (180137 patients), the results were also decreasing in younger men but not in women (Sex-specific AAPC-difference = 2.55, P < 0.001).

Conclusion: Nationwide analysis covering around 98% of the United States population shows an increasing incidence of HCC across all geographical regions, most notably in the South. While younger men experienced decreasing HCC incidence, younger women had a stable trend and this was noted across all regions as well. Our study offers insight into the epidemiology of HCC in different demographic groups across various United States geographical regions. While the reasons contributing to our findings are unclear, they can be related to sex and regional disparities in healthcare access and utilization. Future research is warranted to characterize the temporal change in HCC risk factors across different United States regions.

背景:虽然先前的数据显示美国肝细胞癌(HCC)的发病率在增加,但关于不同人口特异性人群HCC趋势的地理变化的综合和比较数据有限。目的:评估美国不同地理区域的性别和年龄特异性发病率和时间趋势。方法:从美国癌症统计(USCS)数据库中收集年龄调整后的HCC发病率,该数据库涵盖了美国约98%的人口。HCC发生率按性别、年龄和地理区域分层。采用关节点回归法估算年变化百分比(APC)和平均APC (AAPC)。对不同性别的趋势进行两两比较。结果:2001年至2020年,美国USCS数据库中有467344例被诊断为HCC的患者。比率和趋势因地理区域而异。在西部地区(115336例患者),HCC的发病率总体呈上升趋势,老年人的发病率也在上升。然而,当评估年轻人时,男性的HCC发病率下降,但女性没有,性别特异性的aapc绝对差异为2.15 (P = 0.005)。当评估中西部地区(84612例患者)时,也看到了类似的结果。虽然总体人群和老年人的发病率都在上升,但年轻男性的发病率在下降,而女性的发病率则没有下降,性别特异性的aapc绝对差异为1.61 (P < 0.001)。在东北地区(87259例患者),分析显示了类似的结果,年轻男性的HCC发病率下降,但女性的发生率没有下降(性别特异性aapc差异= 3.26,P < 0.001)。最后,当评估南方(180137例患者)时,年轻男性的结果也有所下降,但女性没有(性别特异性aapc差异= 2.55,P < 0.001)。结论:覆盖约98%美国人口的全国性分析显示,HCC在所有地理区域的发病率都在增加,尤其是在南部。虽然年轻男性的HCC发病率下降,但年轻女性的趋势稳定,并且在所有地区都注意到这一点。我们的研究深入了解了HCC在美国不同地理区域不同人口群体中的流行病学。虽然促成我们研究结果的原因尚不清楚,但它们可能与医疗保健获取和利用方面的性别和地区差异有关。未来的研究有必要描述HCC危险因素在美国不同地区的时间变化。
{"title":"Hepatocellular carcinoma national burden across different geographical regions in the United States between 2001 and 2020.","authors":"Yazan Abboud, Raj Malhotra, Muhammad Hassaan Arif Maan, Anna Mathew, Ibrahim Abboud, Chun-Wei Pan, Saqr Alsakarneh, Fouad Jaber, Islam Mohamed, David Kim, Nikolaos T Pyrsopoulos","doi":"10.5662/wjm.v14.i4.95598","DOIUrl":"10.5662/wjm.v14.i4.95598","url":null,"abstract":"<p><strong>Background: </strong>While prior data showed an increasing incidence of hepatocellular carcinoma (HCC) in the United States, there are limited comprehensive and comparative data on the geographical variations of HCC trends in different demographic-specific populations.</p><p><strong>Aim: </strong>To evaluate sex and age-specific incidence rates and time trends in different geographical regions in the United States.</p><p><strong>Methods: </strong>Age-adjusted HCC incidence rates were collected from the United States Cancer Statistics (USCS) database which covers approximately 98% of the population in the United States. HCC rates were stratified by sex, age, and geographical region. annual percentage change (APC) and average APC (AAPC) were estimated using Joinpoint Regression. A pairwise comparison was conducted between sex-specific trends.</p><p><strong>Results: </strong>There were 467344 patients diagnosed with HCC in the United States in the USCS database between 2001 and 2020. The rates and trends varied by geographical region. When looking at the West region (115336 patients), incidence rates of HCC were overall increasing and also increasing in older adults. However, when evaluating younger adults, HCC incidence rates decreased in men but not in women with a sex-specific absolute AAPC-difference of 2.15 (<i>P</i> = 0.005). When evaluating the Midwest region (84612 patients), similar results were seen. While incidence rates were increasing in the overall population and in older adults as well, they were decreasing in younger men but not in women with a sex-specific absolute AAPC-difference of 1.61 (<i>P</i> < 0.001). For the Northeast region (87259 patients), the analysis showed similar results with decreasing HCC incidence rates in younger men but not counterpart women (Sex-specific AAPC-difference = 3.26, <i>P</i> < 0.001). Lastly, when evaluating the south (180137 patients), the results were also decreasing in younger men but not in women (Sex-specific AAPC-difference = 2.55, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Nationwide analysis covering around 98% of the United States population shows an increasing incidence of HCC across all geographical regions, most notably in the South. While younger men experienced decreasing HCC incidence, younger women had a stable trend and this was noted across all regions as well. Our study offers insight into the epidemiology of HCC in different demographic groups across various United States geographical regions. While the reasons contributing to our findings are unclear, they can be related to sex and regional disparities in healthcare access and utilization. Future research is warranted to characterize the temporal change in HCC risk factors across different United States regions.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95598"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biobanks and biomarkers: Their current and future role in biomedical research. 生物银行和生物标记物:它们在生物医学研究中的当前和未来作用。
Pub Date : 2024-12-20 DOI: 10.5662/wjm.v14.i4.91387
Michael Colwill, Samantha Baillie, Richard Pollok, Andrew Poullis

The importance and utility of biobanks has increased exponentially since their inception and creation. Initially used as part of translational research, they now contribute over 40% of data for all cancer research papers in the United States of America and play a crucial role in all aspects of healthcare. Multiple classification systems exist but a simplified approach is to either classify as population-based or disease-oriented entities. Whilst historically publicly funded institutions, there has been a significant increase in industry funded entities across the world which has changed the dynamic of biobanks offering new possibilities but also new challenges. Biobanks face legal questions over data sharing and intellectual property as well as ethical and sustainability questions particularly as the world attempts to move to a low-carbon economy. International collaboration is required to address some of these challenges but this in itself is fraught with complexity and difficulty. This review will examine the current utility of biobanks in the modern healthcare setting as well as the current and future challenges these vital institutions face.

生物银行的重要性和效用自其创立以来呈指数增长。最初用作转化研究的一部分,现在它们为美国所有癌症研究论文提供了超过40%的数据,并在医疗保健的各个方面发挥着至关重要的作用。存在多种分类系统,但一种简化的方法是要么分类为基于人群的实体,要么分类为面向疾病的实体。虽然历史上是公共资助的机构,但世界各地的工业资助实体显著增加,这改变了生物银行的动态,提供了新的可能性,但也带来了新的挑战。生物银行面临着数据共享和知识产权方面的法律问题,以及道德和可持续性问题,尤其是在世界试图转向低碳经济之际。应对其中一些挑战需要国际合作,但这本身就充满了复杂性和困难。这篇综述将研究生物银行在现代医疗环境中的当前效用,以及这些重要机构面临的当前和未来的挑战。
{"title":"Biobanks and biomarkers: Their current and future role in biomedical research.","authors":"Michael Colwill, Samantha Baillie, Richard Pollok, Andrew Poullis","doi":"10.5662/wjm.v14.i4.91387","DOIUrl":"10.5662/wjm.v14.i4.91387","url":null,"abstract":"<p><p>The importance and utility of biobanks has increased exponentially since their inception and creation. Initially used as part of translational research, they now contribute over 40% of data for all cancer research papers in the United States of America and play a crucial role in all aspects of healthcare. Multiple classification systems exist but a simplified approach is to either classify as population-based or disease-oriented entities. Whilst historically publicly funded institutions, there has been a significant increase in industry funded entities across the world which has changed the dynamic of biobanks offering new possibilities but also new challenges. Biobanks face legal questions over data sharing and intellectual property as well as ethical and sustainability questions particularly as the world attempts to move to a low-carbon economy. International collaboration is required to address some of these challenges but this in itself is fraught with complexity and difficulty. This review will examine the current utility of biobanks in the modern healthcare setting as well as the current and future challenges these vital institutions face.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"91387"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Palliative care for end-stage liver disease and acute on chronic liver failure: A systematic review. 终末期肝病和急性慢性肝衰竭的姑息治疗:一项系统综述。
Pub Date : 2024-12-20 DOI: 10.5662/wjm.v14.i4.95904
Vakaola I Pulotu Mafi, Jonathan Soldera

Background: End stage liver disease (ESLD) represents a growing health concern characterized by elevated morbidity and mortality, particularly among individual ineligible for liver transplantation. The demand for palliative care (PC) is pronounced in patients grappling with ESLD and acute on chronic liver failure (ACLF). Unfortunately, the historical underutilization of PC in ESLD patients, despite their substantial needs and those of their family caregivers, underscores the imperative of seamlessly integrating PC principles into routine healthcare practices across the entire disease spectrum.

Aim: To comprehensively investigate the evidence surrounding the benefits of incorporating PC into the comprehensive care plan for individuals confronting ESLD and/or ACLF.

Methods: A systematic search in the Medline (PubMed) database was performed using a predetermined search command, encompassing studies published in English without any restrictions on the publication date. Subsequently, the retrieved studies were manually examined. Simple descriptive analyses were employed to summarize the results.

Results: The search strategies yielded 721 references. Following the final analysis, 32 full-length references met the inclusion criteria and were consequently incorporated into the study. Meticulous data extraction from these 32 studies was undertaken, leading to the execution of a comprehensive narrative systematic review. The review found that PC provides significant benefits, reducing symptom burden, depressive symptoms, readmission rates, and hospital stays. Yet, barriers like the appeal of transplants and misconceptions about PC hinder optimal utilization. Integrating PC early, upon the diagnosis of ESLD and ACLF, regardless of transplant eligibility and availability, improves the quality of life for these patients.

Conclusion: Despite the substantial suffering and poor prognosis associated with ESLD and ACLF, where liver transplantation stands as the only curative treatment, albeit largely inaccessible, PC services have been overtly provided too late in the course of the illness. A comprehensive understanding of PC's pivotal role in treating ESLD and ACLF is crucial for overcoming these barriers, involving healthcare providers, patients, and caregivers.

背景:终末期肝病(ESLD)是一种日益严重的健康问题,其特点是发病率和死亡率升高,特别是在不适合肝移植的个体中。对姑息治疗(PC)的需求是明显的患者与ESLD和急性或慢性肝功能衰竭(ACLF)的斗争。不幸的是,尽管ESLD患者及其家庭护理人员有大量需求,但PC的历史利用不足,强调了将PC原则无缝整合到整个疾病谱系的常规医疗实践中的必要性。目的:全面调查将PC纳入面临ESLD和/或ACLF个体的综合护理计划的益处的证据。方法:在Medline (PubMed)数据库中使用预定的搜索命令进行系统搜索,包括以英文发表的研究,不受出版日期的限制。随后,人工检查检索到的研究。采用简单的描述性分析来总结结果。结果:检索策略共获得文献721篇。经最终分析,32篇全文文献符合纳入标准,纳入本研究。从这32项研究中进行了细致的数据提取,从而进行了全面的叙述系统评价。回顾发现,PC提供了显著的益处,减少了症状负担、抑郁症状、再入院率和住院时间。然而,移植的吸引力和对PC的误解等障碍阻碍了最佳利用。在ESLD和ACLF诊断后,无论移植资格和可用性如何,早期整合PC可改善这些患者的生活质量。结论:尽管与ESLD和ACLF相关的巨大痛苦和预后不良,肝移植是唯一的治疗方法,尽管在很大程度上难以获得,但在疾病过程中,PC服务显然提供得太晚。全面了解PC在治疗ESLD和ACLF中的关键作用对于克服这些障碍至关重要,这些障碍涉及医疗保健提供者、患者和护理人员。
{"title":"Palliative care for end-stage liver disease and acute on chronic liver failure: A systematic review.","authors":"Vakaola I Pulotu Mafi, Jonathan Soldera","doi":"10.5662/wjm.v14.i4.95904","DOIUrl":"10.5662/wjm.v14.i4.95904","url":null,"abstract":"<p><strong>Background: </strong>End stage liver disease (ESLD) represents a growing health concern characterized by elevated morbidity and mortality, particularly among individual ineligible for liver transplantation. The demand for palliative care (PC) is pronounced in patients grappling with ESLD and acute on chronic liver failure (ACLF). Unfortunately, the historical underutilization of PC in ESLD patients, despite their substantial needs and those of their family caregivers, underscores the imperative of seamlessly integrating PC principles into routine healthcare practices across the entire disease spectrum.</p><p><strong>Aim: </strong>To comprehensively investigate the evidence surrounding the benefits of incorporating PC into the comprehensive care plan for individuals confronting ESLD and/or ACLF.</p><p><strong>Methods: </strong>A systematic search in the Medline (PubMed) database was performed using a predetermined search command, encompassing studies published in English without any restrictions on the publication date. Subsequently, the retrieved studies were manually examined. Simple descriptive analyses were employed to summarize the results.</p><p><strong>Results: </strong>The search strategies yielded 721 references. Following the final analysis, 32 full-length references met the inclusion criteria and were consequently incorporated into the study. Meticulous data extraction from these 32 studies was undertaken, leading to the execution of a comprehensive narrative systematic review. The review found that PC provides significant benefits, reducing symptom burden, depressive symptoms, readmission rates, and hospital stays. Yet, barriers like the appeal of transplants and misconceptions about PC hinder optimal utilization. Integrating PC early, upon the diagnosis of ESLD and ACLF, regardless of transplant eligibility and availability, improves the quality of life for these patients.</p><p><strong>Conclusion: </strong>Despite the substantial suffering and poor prognosis associated with ESLD and ACLF, where liver transplantation stands as the only curative treatment, albeit largely inaccessible, PC services have been overtly provided too late in the course of the illness. A comprehensive understanding of PC's pivotal role in treating ESLD and ACLF is crucial for overcoming these barriers, involving healthcare providers, patients, and caregivers.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95904"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative evaluation of artificial intelligence systems' accuracy in providing medical drug dosages: A methodological study. 人工智能系统提供医疗药物剂量准确性的比较评价:一项方法学研究。
Pub Date : 2024-12-20 DOI: 10.5662/wjm.v14.i4.92802
Swaminathan Ramasubramanian, Sangeetha Balaji, Tejashri Kannan, Naveen Jeyaraman, Shilpa Sharma, Filippo Migliorini, Suhasini Balasubramaniam, Madhan Jeyaraman

Background: Medication errors, especially in dosage calculation, pose risks in healthcare. Artificial intelligence (AI) systems like ChatGPT and Google Bard may help reduce errors, but their accuracy in providing medication information remains to be evaluated.

Aim: To evaluate the accuracy of AI systems (ChatGPT 3.5, ChatGPT 4, Google Bard) in providing drug dosage information per Harrison's Principles of Internal Medicine.

Methods: A set of natural language queries mimicking real-world medical dosage inquiries was presented to the AI systems. Responses were analyzed using a 3-point Likert scale. The analysis, conducted with Python and its libraries, focused on basic statistics, overall system accuracy, and disease-specific and organ system accuracies.

Results: ChatGPT 4 outperformed the other systems, showing the highest rate of correct responses (83.77%) and the best overall weighted accuracy (0.6775). Disease-specific accuracy varied notably across systems, with some diseases being accurately recognized, while others demonstrated significant discrepancies. Organ system accuracy also showed variable results, underscoring system-specific strengths and weaknesses.

Conclusion: ChatGPT 4 demonstrates superior reliability in medical dosage information, yet variations across diseases emphasize the need for ongoing improvements. These results highlight AI's potential in aiding healthcare professionals, urging continuous development for dependable accuracy in critical medical situations.

背景:用药错误,尤其是剂量计算错误,给医疗保健带来风险。ChatGPT和b谷歌Bard等人工智能(AI)系统可能有助于减少错误,但它们在提供药物信息方面的准确性仍有待评估。目的:评估人工智能系统(ChatGPT 3.5, ChatGPT 4, b谷歌Bard)根据《哈里森内科原理》提供药物剂量信息的准确性。方法:向人工智能系统提供一组模拟真实用药剂量查询的自然语言查询。使用3点李克特量表分析回答。使用Python及其库进行的分析侧重于基本统计、整体系统准确性以及疾病特异性和器官系统准确性。结果:ChatGPT 4表现出最高的正确率(83.77%)和最佳的综合加权准确率(0.6775)。不同系统的疾病特异性准确性差异显著,一些疾病被准确识别,而另一些疾病则表现出显著差异。器官系统的准确性也显示出不同的结果,强调系统特定的优势和劣势。结论:ChatGPT 4在医疗剂量信息方面表现出卓越的可靠性,但不同疾病的差异强调需要不断改进。这些结果突出了人工智能在帮助医疗专业人员方面的潜力,敦促在危急医疗情况下不断发展可靠的准确性。
{"title":"Comparative evaluation of artificial intelligence systems' accuracy in providing medical drug dosages: A methodological study.","authors":"Swaminathan Ramasubramanian, Sangeetha Balaji, Tejashri Kannan, Naveen Jeyaraman, Shilpa Sharma, Filippo Migliorini, Suhasini Balasubramaniam, Madhan Jeyaraman","doi":"10.5662/wjm.v14.i4.92802","DOIUrl":"10.5662/wjm.v14.i4.92802","url":null,"abstract":"<p><strong>Background: </strong>Medication errors, especially in dosage calculation, pose risks in healthcare. Artificial intelligence (AI) systems like ChatGPT and Google Bard may help reduce errors, but their accuracy in providing medication information remains to be evaluated.</p><p><strong>Aim: </strong>To evaluate the accuracy of AI systems (ChatGPT 3.5, ChatGPT 4, Google Bard) in providing drug dosage information per Harrison's Principles of Internal Medicine.</p><p><strong>Methods: </strong>A set of natural language queries mimicking real-world medical dosage inquiries was presented to the AI systems. Responses were analyzed using a 3-point Likert scale. The analysis, conducted with Python and its libraries, focused on basic statistics, overall system accuracy, and disease-specific and organ system accuracies.</p><p><strong>Results: </strong>ChatGPT 4 outperformed the other systems, showing the highest rate of correct responses (83.77%) and the best overall weighted accuracy (0.6775). Disease-specific accuracy varied notably across systems, with some diseases being accurately recognized, while others demonstrated significant discrepancies. Organ system accuracy also showed variable results, underscoring system-specific strengths and weaknesses.</p><p><strong>Conclusion: </strong>ChatGPT 4 demonstrates superior reliability in medical dosage information, yet variations across diseases emphasize the need for ongoing improvements. These results highlight AI's potential in aiding healthcare professionals, urging continuous development for dependable accuracy in critical medical situations.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"92802"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing outcomes: Implementing enhanced recovery after surgery in orthopedic surgery. 优化结果:在骨科手术中实施增强术后恢复。
Pub Date : 2024-12-20 DOI: 10.5662/wjm.v14.i4.95558
Sathish Muthu, Madhan Jeyaraman, Naveen Jeyaraman, Swaminathan Ramasubramanian

In the realm of orthopedics, the adoption of enhanced recovery after surgery (ERAS) protocols marks a significant stride towards enhancing patient well-being. By embracing a holistic approach that encompasses preoperative counseling, dietary optimization, minimally invasive procedures, and early postoperative mobilization, these protocols have ushered in a new era of surgical care. Despite encountering hurdles like resistance to change and resource allocation challenges, the efficacy of ERAS protocols in improving clinical outcomes is undeniable. Noteworthy benefits include shortened hospital stays and bolstered improved patient-safety measures. Looking ahead, the horizon for ERAS in orthopedics appears bright, with an emphasis on tailoring care to individual needs, integrating cutting-edge technologies, and perpetuating research endeavors. This shift towards a more personalized, streamlined, and cost-efficient model of care underscores the transformative potential of ERAS in reshaping not only orthopedic surgery but also the journey to patient recovery. This editorial details the scope and future of ERAS in the orthopedic specialty.

在骨科领域,采用增强术后恢复(ERAS)协议标志着朝着提高患者福祉迈出了重要的一步。通过采用包括术前咨询、饮食优化、微创手术和术后早期活动在内的整体方法,这些方案开创了外科护理的新时代。尽管遇到了诸如变革阻力和资源分配挑战等障碍,但ERAS方案在改善临床结果方面的功效是不可否认的。值得注意的好处包括缩短住院时间和加强改善患者安全措施。展望未来,骨科领域的ERAS前景光明,其重点是根据个人需求量身定制护理,整合尖端技术,并使研究努力永久化。这种向更个性化、更精简、更具成本效益的护理模式的转变,突显了ERAS在重塑骨科手术以及患者康复过程中的变革潜力。这篇社论详细介绍了骨科专业ERAS的范围和未来。
{"title":"Optimizing outcomes: Implementing enhanced recovery after surgery in orthopedic surgery.","authors":"Sathish Muthu, Madhan Jeyaraman, Naveen Jeyaraman, Swaminathan Ramasubramanian","doi":"10.5662/wjm.v14.i4.95558","DOIUrl":"10.5662/wjm.v14.i4.95558","url":null,"abstract":"<p><p>In the realm of orthopedics, the adoption of enhanced recovery after surgery (ERAS) protocols marks a significant stride towards enhancing patient well-being. By embracing a holistic approach that encompasses preoperative counseling, dietary optimization, minimally invasive procedures, and early postoperative mobilization, these protocols have ushered in a new era of surgical care. Despite encountering hurdles like resistance to change and resource allocation challenges, the efficacy of ERAS protocols in improving clinical outcomes is undeniable. Noteworthy benefits include shortened hospital stays and bolstered improved patient-safety measures. Looking ahead, the horizon for ERAS in orthopedics appears bright, with an emphasis on tailoring care to individual needs, integrating cutting-edge technologies, and perpetuating research endeavors. This shift towards a more personalized, streamlined, and cost-efficient model of care underscores the transformative potential of ERAS in reshaping not only orthopedic surgery but also the journey to patient recovery. This editorial details the scope and future of ERAS in the orthopedic specialty.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95558"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Point-of-care ultrasound in nephrology: A private practice viewpoint. 点护理超声在肾脏病:私人执业的观点。
Pub Date : 2024-12-20 DOI: 10.5662/wjm.v14.i4.95685
Rajiv Sinanan, Afsheen Moshtaghi, Abhilash Koratala

Point-of-care ultrasound (POCUS) is a limited ultrasound examination performed by the clinician at the bedside, emerging as a complement to physical examination across various medical specialties. In the field of nephrology, its integration has been gradual, primarily limited to guiding procedures like temporary dialysis catheter placement or, in some cases, diagnostic kidney ultrasounds. In reality, the assessment of hemodynamic status at the bedside holds immense value for nephrologists, yet there exists limited awareness among practitioners regarding its implementation. While there is a growing trend towards incorporating multi-organ POCUS training in fellowship programs, private practice nephrologists remain relatively uninformed. This discussion explores the untapped potential of POCUS as a valuable diagnostic tool in everyday nephrology practice, demonstrating its effectiveness in diverse clinical settings, ranging from medical wards to outpatient dialysis units. Additionally, we delve into the challenges hindering its widespread adoption and consider the future trajectory of this innovative approach.

即时超声(POCUS)是临床医生在床边进行的一种有限的超声检查,作为各种医学专业体检的补充。在肾脏病学领域,它的整合一直是渐进的,主要局限于指导手术,如临时透析导管放置,或者在某些情况下,肾脏超声诊断。在现实中,在床边的血液动力学状态的评估具有巨大的价值肾病学家,但存在有限的认识,在从业人员对其实施。虽然在奖学金项目中纳入多器官POCUS培训的趋势日益增长,但私人执业肾病学家仍然相对不了解。本讨论探讨POCUS作为日常肾脏病实践中有价值的诊断工具的未开发潜力,展示其在各种临床环境中的有效性,从内科病房到门诊透析单位。此外,我们还深入研究了阻碍其广泛采用的挑战,并考虑了这种创新方法的未来轨迹。
{"title":"Point-of-care ultrasound in nephrology: A private practice viewpoint.","authors":"Rajiv Sinanan, Afsheen Moshtaghi, Abhilash Koratala","doi":"10.5662/wjm.v14.i4.95685","DOIUrl":"10.5662/wjm.v14.i4.95685","url":null,"abstract":"<p><p>Point-of-care ultrasound (POCUS) is a limited ultrasound examination performed by the clinician at the bedside, emerging as a complement to physical examination across various medical specialties. In the field of nephrology, its integration has been gradual, primarily limited to guiding procedures like temporary dialysis catheter placement or, in some cases, diagnostic kidney ultrasounds. In reality, the assessment of hemodynamic status at the bedside holds immense value for nephrologists, yet there exists limited awareness among practitioners regarding its implementation. While there is a growing trend towards incorporating multi-organ POCUS training in fellowship programs, private practice nephrologists remain relatively uninformed. This discussion explores the untapped potential of POCUS as a valuable diagnostic tool in everyday nephrology practice, demonstrating its effectiveness in diverse clinical settings, ranging from medical wards to outpatient dialysis units. Additionally, we delve into the challenges hindering its widespread adoption and consider the future trajectory of this innovative approach.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95685"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remission of type 2 diabetes mellitus: Emerging concepts and proposed diagnostic criteria. 2型糖尿病的缓解:新兴概念和建议的诊断标准。
Pub Date : 2024-12-20 DOI: 10.5662/wjm.v14.i4.95210
Arkiath Veettil Raveendran

The remission of type 2 diabetes mellitus (T2DM) is a topic that has been widely discussed recently, and it gives new hope for people with T2DM. Achievement of normal blood glucose levels or levels below the diagnostic threshold for T2DM without pharmacotherapy among people with T2DM after metabolic surgery and carbohydrate or calorie-restricted diet paved the way for more enthusiastic research in this area. There is a lot of confusion regarding the appropriate terminology and definition of remission of T2DM. In this short review, we briefly analyzed the emerging concepts and proposed criteria for diagnosing remission of T2DM, which will be helpful for healthcare providers and people with T2DM.

2型糖尿病(T2DM)的缓解是近年来广泛讨论的话题,它给T2DM患者带来了新的希望。T2DM患者在接受代谢手术和碳水化合物或卡路里限制饮食后,在没有药物治疗的情况下血糖水平达到正常或低于T2DM诊断阈值,为该领域更积极的研究铺平了道路。关于T2DM缓解的适当术语和定义有很多混淆。在这篇简短的综述中,我们简要地分析了T2DM缓解的新概念和诊断标准,这将对医疗保健提供者和T2DM患者有所帮助。
{"title":"Remission of type 2 diabetes mellitus: Emerging concepts and proposed diagnostic criteria.","authors":"Arkiath Veettil Raveendran","doi":"10.5662/wjm.v14.i4.95210","DOIUrl":"10.5662/wjm.v14.i4.95210","url":null,"abstract":"<p><p>The remission of type 2 diabetes mellitus (T2DM) is a topic that has been widely discussed recently, and it gives new hope for people with T2DM. Achievement of normal blood glucose levels or levels below the diagnostic threshold for T2DM without pharmacotherapy among people with T2DM after metabolic surgery and carbohydrate or calorie-restricted diet paved the way for more enthusiastic research in this area. There is a lot of confusion regarding the appropriate terminology and definition of remission of T2DM. In this short review, we briefly analyzed the emerging concepts and proposed criteria for diagnosing remission of T2DM, which will be helpful for healthcare providers and people with T2DM.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95210"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diabetic retinopathy: A review on its pathophysiology and novel treatment modalities. 糖尿病视网膜病变:病理生理学和新的治疗方式的综述。
Pub Date : 2024-12-20 DOI: 10.5662/wjm.v14.i4.95881
Arvind Kumar Morya, Prasanna Venkatesh Ramesh, Prateek Nishant, Kirandeep Kaur, Bharat Gurnani, Aarti Heda, Sarika Salodia

Diabetes mellitus (DM) is a chronic metabolic non-communicable disease with the ability to cause serious microvascular and macrovascular complications throughout the body, including in the eye. Diabetic retinopathy (DR), present in one-third of patients with diabetes, is a vision-threatening complication caused by uncontrolled diabetes, which greatly affects the retinal blood vessels and the light-sensitive inner retina, eventually leading to blindness. Several epidemiological studies elucidate that DR can vary by age of onset, duration, types of diabetes, and ethnicity. Recent studies show that the pathogenesis of diabetic retinopathy has spread its roots beyond merely being the result of hyperglycemia. The complexity of its etiopathology and diagnosis makes therapeutic intervention challenging. This review throws light on the pathological processes behind DR, the cascade of events that follow it, as well as the available and emerging treatment options.

糖尿病(DM)是一种慢性代谢性非传染性疾病,可导致全身包括眼部的严重微血管和大血管并发症。糖尿病视网膜病变(DR)存在于三分之一的糖尿病患者中,是由糖尿病不受控制引起的一种威胁视力的并发症,它极大地影响了视网膜血管和光敏的内视网膜,最终导致失明。一些流行病学研究表明,DR可能因发病年龄、病程、糖尿病类型和种族而异。最近的研究表明,糖尿病视网膜病变的发病机制已经不仅仅是高血糖的结果。其病因和诊断的复杂性使治疗干预具有挑战性。这篇综述揭示了DR背后的病理过程、随后发生的一系列事件,以及现有的和新出现的治疗方案。
{"title":"Diabetic retinopathy: A review on its pathophysiology and novel treatment modalities.","authors":"Arvind Kumar Morya, Prasanna Venkatesh Ramesh, Prateek Nishant, Kirandeep Kaur, Bharat Gurnani, Aarti Heda, Sarika Salodia","doi":"10.5662/wjm.v14.i4.95881","DOIUrl":"10.5662/wjm.v14.i4.95881","url":null,"abstract":"<p><p>Diabetes mellitus (DM) is a chronic metabolic non-communicable disease with the ability to cause serious microvascular and macrovascular complications throughout the body, including in the eye. Diabetic retinopathy (DR), present in one-third of patients with diabetes, is a vision-threatening complication caused by uncontrolled diabetes, which greatly affects the retinal blood vessels and the light-sensitive inner retina, eventually leading to blindness. Several epidemiological studies elucidate that DR can vary by age of onset, duration, types of diabetes, and ethnicity. Recent studies show that the pathogenesis of diabetic retinopathy has spread its roots beyond merely being the result of hyperglycemia. The complexity of its etiopathology and diagnosis makes therapeutic intervention challenging. This review throws light on the pathological processes behind DR, the cascade of events that follow it, as well as the available and emerging treatment options.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"95881"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of molecular imaging in prognosis, diagnosis, and treatment of gastrointestinal cancers: An update on new therapeutic methods. 分子影像学在胃肠道肿瘤预后、诊断和治疗中的作用:新治疗方法的最新进展。
Pub Date : 2024-12-20 DOI: 10.5662/wjm.v14.i4.93461
Mobina Fathi, Hayder Jasim Taher, Sabah Jassim Al-Rubiae, Shirin Yaghoobpoor, Ashkan Bahrami, Reza Eshraghi, Hossein Sadri, Mahsa Asadi Anar, Ali Gholamrezanezhad

One of the leading causes of cancer-related death is gastrointestinal cancer, which has a significant morbidity and mortality rate. Although preoperative risk assessment is essential for directing patient care, its biological behavior cannot be accurately predicted by conventional imaging investigations. Potential pathophysiological information in anatomical imaging that cannot be visually identified can now be converted into high-dimensional quantitative image features thanks to the developing discipline of molecular imaging. In order to enable molecular tissue profile in vivo, molecular imaging has most recently been utilized to phenotype the expression of single receptors and targets of biological therapy. It is expected that molecular imaging will become increasingly important in the near future, driven by the expanding range of biological therapies for cancer. With this live molecular fingerprinting, molecular imaging can be utilized to drive expression-tailored customized therapy. The technical aspects of molecular imaging are first briefly discussed in this review, followed by an examination of the most recent research on the diagnosis, prognosis, and potential future clinical methods of molecular imaging for GI tract malignancies.

胃肠道癌是癌症相关死亡的主要原因之一,其发病率和死亡率都很高。尽管术前风险评估对指导患者护理至关重要,但其生物学行为不能通过常规影像学调查准确预测。由于分子成像学科的发展,解剖成像中无法视觉识别的潜在病理生理信息现在可以转化为高维定量的图像特征。为了使分子组织在体内的轮廓,分子成像最近被用于表型单一受体的表达和生物治疗的目标。预计在不久的将来,随着癌症生物治疗范围的扩大,分子成像将变得越来越重要。有了这种活分子指纹,分子成像可以用来驱动表达定制治疗。本文首先简要讨论了分子成像的技术方面,然后对胃肠道恶性肿瘤分子成像的诊断、预后和潜在的未来临床方法的最新研究进行了检查。
{"title":"Role of molecular imaging in prognosis, diagnosis, and treatment of gastrointestinal cancers: An update on new therapeutic methods.","authors":"Mobina Fathi, Hayder Jasim Taher, Sabah Jassim Al-Rubiae, Shirin Yaghoobpoor, Ashkan Bahrami, Reza Eshraghi, Hossein Sadri, Mahsa Asadi Anar, Ali Gholamrezanezhad","doi":"10.5662/wjm.v14.i4.93461","DOIUrl":"10.5662/wjm.v14.i4.93461","url":null,"abstract":"<p><p>One of the leading causes of cancer-related death is gastrointestinal cancer, which has a significant morbidity and mortality rate. Although preoperative risk assessment is essential for directing patient care, its biological behavior cannot be accurately predicted by conventional imaging investigations. Potential pathophysiological information in anatomical imaging that cannot be visually identified can now be converted into high-dimensional quantitative image features thanks to the developing discipline of molecular imaging. In order to enable molecular tissue profile <i>in vivo</i>, molecular imaging has most recently been utilized to phenotype the expression of single receptors and targets of biological therapy. It is expected that molecular imaging will become increasingly important in the near future, driven by the expanding range of biological therapies for cancer. With this live molecular fingerprinting, molecular imaging can be utilized to drive expression-tailored customized therapy. The technical aspects of molecular imaging are first briefly discussed in this review, followed by an examination of the most recent research on the diagnosis, prognosis, and potential future clinical methods of molecular imaging for GI tract malignancies.</p>","PeriodicalId":94271,"journal":{"name":"World journal of methodology","volume":"14 4","pages":"93461"},"PeriodicalIF":0.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11287540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142879369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World journal of methodology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1